TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22869829

Group type: EXPERIMENTAL
Intervention: Montelukast (4 or 5 mg daily for 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 46
Study: 20331663

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 169

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Never-institutionalized group
Number of subjects: 169
Study: 18559683

Group type: EXPERIMENTAL
Intervention: Computer training and Internet usage
Number of subjects: 191

Group type: COMPARATOR
Intervention: Training-no intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: No training-no intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: No interest in computer use
Number of subjects: 191
Study: 16019363

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous combined CEE/MPA 0.625 mg/day and 5 mg/day
Number of subjects: 80
Study: 12447954

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg/day PO
Number of subjects: 186

Group type: COMPARATOR
Intervention: Low-dose amphotericin B 0.2 mg/kg/day IV
Number of subjects: 186
Study: 10485779

Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg three times on the first day and 300 mg three times on the second day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8765815

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (220 micrograms or 440 micrograms)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral prednisone (10 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 1931395

Group type: EXPERIMENTAL
Intervention: Midazolam 0.42 mg kg‐1 i.v. followed by an infusion of midazolam 0.125 mg kg‐1 for 1 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Thiopentone (control)
Number of subjects: 8
Study: 6808553

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (non-anxious subjects)
Number of subjects: 16
Study: 31201146

Group type: EXPERIMENTAL
Intervention: KAASER (500 mg, three times a day for 2 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dimethicone (500 mg, three times a day for 2 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (500 mg, three times a day for 2 weeks)
Number of subjects: 106
Study: 28385948

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAS
Number of subjects: 289

Group type: COMPARATOR
Intervention: HeartMate II (HMII) LVAS
Number of subjects: 289
Study: 26509986

Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB/βTCP with guided bone regeneration (GBR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional implant placement
Number of subjects: 14
Study: 24021603

Group type: EXPERIMENTAL
Intervention: Biorhythmically defined vasomotion stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21251359

Group type: EXPERIMENTAL
Intervention: CCERW clinical prediction rule
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: CCERW
Number of subjects: 539

Group type: COMPARATOR
Intervention: PSI, CURB65, CRB65
Number of subjects: 539
Study: 19898698

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day)
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Standard-dose simvastatin (20 mg/day to 40 mg/day)
Number of subjects: 8888
Study: 17123915

Group type: EXPERIMENTAL
Intervention: Fluoride-containing materials (e.g., Fuji IX - FIX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (C) and other fluoride-containing materials (F, H, V)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fluoride release from FIX
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fluoride release from CF
Number of subjects: 108
Study: 14701770

Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 658

Group type: COMPARATOR
Intervention: Axillary radiotherapy
Number of subjects: 658
Study: 12212341

Group type: EXPERIMENTAL
Intervention: Glynase Prestabs (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Generic tablets (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glynase Prestabs (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Generic tablets (Group B)
Number of subjects: 30
Study: 9258217

Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.2 mg/mL, applied for 2 minutes
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.4 mg/mL, applied for 4 minutes
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mitomycin, 0.4 mg/mL, applied for 2 minutes
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 8438713

Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA) followed by adjunctive PTCA
Number of subjects: 53
Study: 3553759

Group type: EXPERIMENTAL
Intervention: Isoproterenol and atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methacholine and histamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rapid, shallow breathing with methacholine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow, deep breathing with methacholine
Number of subjects: 12
Study: 31953058

Group type: EXPERIMENTAL
Intervention: Rhexis-fixated IOL
Number of subjects: 56

Group type: COMPARATOR
Intervention: C-loop haptic IOL
Number of subjects: 56

Group type: COMPARATOR
Intervention: Plate-haptic IOL
Number of subjects: 56
Study: 28806104

Group type: EXPERIMENTAL
Intervention: Active rTMS (Left DLPFC, 10 Hz, 110% rMT, 4000 pulses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 27009938

Group type: EXPERIMENTAL
Intervention: Primary Debulking Surgery (PDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by Interval Debulking Surgery (NACT-IDS)
Number of subjects: 0
Study: 25760680

Group type: EXPERIMENTAL
Intervention: GIK solution (insulin 0.1 IU kg(‐1) h(‐1) and an infusion of 30% dextrose and 80 mmol l(‐1) potassium at 0.5 ml kg(‐1) h(‐1))
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 106
Study: 23780952

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 21195294

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 79
Study: 19553398

Group type: EXPERIMENTAL
Intervention: Presence of atrial fibrillation (AF) in CHF patients
Number of subjects: 53969
Study: 17892983

Group type: EXPERIMENTAL
Intervention: Physiologic guidance with fractional flow reserve (FFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 0
Study: 15079782

Group type: EXPERIMENTAL
Intervention: TachoComb H patches
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard compression with surgical swabs (Control)
Number of subjects: 24
Study: 11233879

Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 9031957

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with adrenaline 1:200 000 (n = 500)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with 10 micrograms sufentanil (n = 500)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 1000
Study: 7838644

Group type: EXPERIMENTAL
Intervention: LAT gel (4% lidocaine, 1:2000 adrenaline, 0.5% tetracaine)
Number of subjects: 95

Group type: COMPARATOR
Intervention: TAC gel (0.5% tetracaine, 1:2000 adrenaline, 11.8% cocaine)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: LAT gel
Number of subjects: 95

Group type: COMPARATOR
Intervention: TAC gel
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: LAT gel and TAC gel
Number of subjects: 95
Study: 2197909

Group type: EXPERIMENTAL
Intervention: Hearing aid (n = 95)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Waiting list (n = 99)
Number of subjects: 194
Study: 699788

Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg/d or 3 x 80 mg/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propranolol (with spironolactone 50 mg/d, thiabutazide 5 mg/d, and dihydralazine 3 x 25 mg/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chronic beta-adrenergic blockade
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 61
Study: 30633058

Group type: EXPERIMENTAL
Intervention: Preoperative music intervention
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Pre- and intraoperative music intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (no music intervention)
Number of subjects: 195
Study: 31223480

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 28494509

Group type: EXPERIMENTAL
Intervention: 19 mg ferrous gluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 38 mg ferrous gluconate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pill
Number of subjects: 0
Study: 25947181

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary self-management intervention (8-week health education, exercise sessions, individual empowerment counseling, followed by 16-week self-help group activities)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary self-management intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 43
Study: 26552322

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic dose reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily perphenazine dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily perphenazine dosing
Number of subjects: 0
Study: 23168366

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (2.5 mg/kg per week equivalent, either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, intravenously)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 820
Study: 19443169

Group type: EXPERIMENTAL
Intervention: Patient self-completion concordance forms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual information and instruction on how to use the medicine (Control)
Number of subjects: 0
Study: 18379357

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vandetanib 200 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Number of subjects: 53
Study: 16530990

Group type: EXPERIMENTAL
Intervention: Early post‐discharge developmental mother‐child intervention program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 14673218

Group type: EXPERIMENTAL
Intervention: Trazodone CR (150 mg)
Number of subjects: 549
Study: 10807482

Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL ECT) at high dosage (150% or 500% above seizure threshold)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT) at high dosage (150% above seizure threshold)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-dosage Unilateral ECT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moderate-dosage Unilateral ECT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ECT (all groups)
Number of subjects: 80
Study: 9144763

Group type: EXPERIMENTAL
Intervention: Counseling and self-help materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 7695258

Group type: EXPERIMENTAL
Intervention: 50 mg genaconazole tablets orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg genaconazole intravenous infusion
Number of subjects: 12
Study: 3234625

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (415 pmol bolus injection followed by infusion to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29290000

Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine (3 g, two oral doses)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard-of-care antibiotic therapy (control group)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Number of subjects: 216
Study: 26610176

Group type: EXPERIMENTAL
Intervention: Home-based care (H)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Facility-based care (F)
Number of subjects: 426
Study: 25384116

Group type: EXPERIMENTAL
Intervention: Lavender-thymol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23702435

Group type: EXPERIMENTAL
Intervention: Sublingual ketorolac (0.5 mg/kg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sublingual tramadol (2 mg/kg)
Number of subjects: 131
Study: 20464263

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 149
Study: 18379366

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 16801333

Group type: EXPERIMENTAL
Intervention: Basic communication skills training programme (BT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic communication skills training programme (BT) with consolidation workshops (CW)
Number of subjects: 0
Study: 14685040

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Cry j 1 at doses of 0.01 microg/ml, 0.1 microg/ml, 1 microg/ml, and 10 microg/ml.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anti-IgE therapy.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hyposensitization therapy (duration not specified).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy.
Number of subjects: 22
Study: 10957832

Group type: EXPERIMENTAL
Intervention: Sweetener
Number of subjects: 25
Study: 8996937

Group type: EXPERIMENTAL
Intervention: ETS exposure (Group II)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Biomass exposure (Group III)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both ETS and biomass exposure
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: ETS exposure with exposure index (EI) of 50 or more
Number of subjects: 172
Study: 7942121

Group type: COMPARATOR
Intervention: Conventional radiometric ingestion assay (IN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminol-enhanced chemiluminescence (LCL) in response to phorbol esters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminol-enhanced chemiluminescence (LCL) during phagocytosis of opsonized Staphylococcus aureus (STLCL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro data at glucose concentrations > or = 13.8 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro data at glucose levels > or = 27.75 mmol/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correlation of peak LCL response and IN in control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of peak LCL response and IN in diabetic patients
Number of subjects: 0
Study: 3496186

Group type: EXPERIMENTAL
Intervention: Enteric-coated fenoprofen calcium (600 mg q.i.d.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plain fenoprofen calcium (600 mg q.i.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both formulations (enteric-coated and plain)
Number of subjects: 32
Study: 31375042

Group type: EXPERIMENTAL
Intervention: rtCGM (Dexcom G5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: iscCGM (Freestyle Libre)
Number of subjects: 40

Group type: COMPARATOR
Intervention: iscCGM switching to rtCGM
Number of subjects: 40
Study: 29354932

Group type: EXPERIMENTAL
Intervention: Combined therapy (heat sensitive moxibustion + acupoint injection)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Heat sensitive moxibustion
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (intravenous drip of cefoxitin sodium)
Number of subjects: 210
Study: 27394380

Group type: EXPERIMENTAL
Intervention: Bright white light therapy using a Litebook treatment device for 30 minutes daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim red light therapy using a Litebook treatment device for 30 minutes daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright white light therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim red light therapy
Number of subjects: 0
Study: 24824768

Group type: EXPERIMENTAL
Intervention: R-maintenance (rituximab maintenance) every 2 months for 2 years
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: R-maintenance (rituximab maintenance)
Number of subjects: 545
Study: 22417252

Group type: EXPERIMENTAL
Intervention: Closure with a percutaneous device
Number of subjects: 909

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 909
Study: 20461068

Group type: COMPARATOR
Intervention: Monotherapy (peginterferon alpha-2a 180 microg weekly plus placebo)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon alpha-2a weekly plus ribavirin 1,000 or 1,200 mg daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 138
Study: 18852544

Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol per day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol per day
Number of subjects: 216

Group type: COMPARATOR
Intervention: 0 IU cholecalciferol per day (placebo)
Number of subjects: 216
Study: 16900385

Group type: EXPERIMENTAL
Intervention: Standard infusion therapy with acute medical intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard infusion therapy with acute medical intervention plus psychotherapeutic intervention
Number of subjects: 93
Study: 14657697

Group type: EXPERIMENTAL
Intervention: Withdrawal of cyclosporine A (CsA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuation of cyclosporine A (CsA)
Number of subjects: 24
Study: 10811675

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m²
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m²
Number of subjects: 104

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 104
Study: 8772621

Group type: EXPERIMENTAL
Intervention: Metformin (up to 2000 mg day‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin (in normal weight subgroup)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin (in overweight subgroup)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 60
Study: 20169701

Group type: EXPERIMENTAL
Intervention: Needle biopsy (Tru-cut R) of the testis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open testicular biopsy
Number of subjects: 45
Study: 6133791

Group type: EXPERIMENTAL
Intervention: Naproxen (Naprosyn)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31481553

Group type: EXPERIMENTAL
Intervention: ICAN Discussion Aid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control encounters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ICAN encounters
Number of subjects: 100
Study: 30153782

Group type: EXPERIMENTAL
Intervention: Liberal fluid resuscitation (≥ 3250 mL of fluid administered)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: High fluid group (≥ 3250 mL of fluid administered)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Liberal fluid group and high fluid group in patients with EuroSCORE II ≥ 0.9
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conservative fluid resuscitation
Number of subjects: 144
Study: 26352680

Group type: EXPERIMENTAL
Intervention: Obesity defined by Body Mass Index (BMI)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Obesity defined by Waist-to-Hip Ratio (WHR)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Normal WHR and BMI
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: WHR
Number of subjects: 2300
Study: 24232052

Group type: EXPERIMENTAL
Intervention: Water-jet assisted POEM (WJ group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional POEM technique (C group)
Number of subjects: 100
Study: 21789587

Group type: COMPARATOR
Intervention: Standard palliative care consultation (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with high anxiety levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with estimated survival of >12 weeks
Number of subjects: 80
Study: 21225177

Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometer
Number of subjects: 17

Group type: COMPARATOR
Intervention: Flow-oriented incentive spirometer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Number of subjects: 17
Study: 17666464

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in women with type 1 diabetes
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in women with type 2 diabetes
Number of subjects: 57
Study: 15799079

Group type: EXPERIMENTAL
Intervention: Integrated emotion‐oriented care
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study: 12038872

Group type: COMPARATOR
Intervention: Interferon-alpha (6 MU/m² body surface area for 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamivudine (3 mg/kg once daily in children up to 12 years of age)
Number of subjects: 0